Adding Navitoclax to Ruxolitinib Shows Potential in JAK-Resistant Myelofibrosis
January 19th 2021In an interview with Targeted Oncology, Naveen Pemmaraju, MD, discussed the potential role of an add-back strategy as treatment of patients with myelofibrosis who no longer benefited from prior ruxolitinib.
Watch
Ivosidenib Produces Encouraging OS Data in Previously Treated Cholangiocarcinoma
January 18th 2021Andrew X. Zhu, MD, PhD, discusses the final results from the phase 3 ClarIDHy study of ivosidenib versus placebo as treatment of patients with previously treated cholangiocarcinoma and an IDH1 mutation.
Watch
Safety Findings Appear Encouraging for REGN5458 in Relapsed/Refractory Myeloma
January 14th 2021Deepu Madduri, MD, discusses the safety findings from a first-in-human phase 1 study of REGN5458, a BCMA x CD3 bispecific monoclonal antibody, as treatment of patients with relapsed/refractory multiple myeloma.
Watch
Older Patients With iNHL Experience Similar Benefit to Younger Population in MAGNIFY Study
January 4th 2021David J. Andorsky, MD, discusses the findings from a subgroup analysis of patients with relapsed/refractory indolent non-Hodgkin lymphoma over the age of 70 in the phase 3b MAGNIFY clinical trial.
Watch